FermaVir Pharmaceuticals, Inc. Announces FDA Response Supports Company’s Development Timelines For Key Investigational New Drug Application

NEW YORK--(BUSINESS WIRE)--April 17, 2006--FermaVir Pharmaceuticals, Inc., (OTCBB:FMVR - News), committed to the development of breakthrough antiviral drugs and other therapies, announced today that the U.S. Food and Drug Administration (FDA) has responded to its pre-Investigational New Drug (IND) application for a novel antiviral drug candidate to address the potentially serious and debilitating viral condition known as shingles. The FDA response will enable FermaVir to proceed with clinical development of a novel antiviral drug candidate for the treatment of shingles.
MORE ON THIS TOPIC